It is very uncertain whether azithromycin changes adverse events (ITT analysis) compared with amoxicillin (very low certainty).
Carbacephem may leads to lower resolution of symptoms post‐treatment (ITT analysis) compared with penicillin (low certainty).
Carbacephem showed no clear difference in resolution of symptoms post‐treatment (evaluable participants) compared with penicillin (low certainty).
Carbacephem showed no clear difference in incidence of relapse (evaluable participants) compared with penicillin (low certainty).
Carbacephem showed no clear difference in adverse events (ITT analysis) compared with penicillin (low certainty).
It is very uncertain whether cephalosporins changes resolution of symptoms post‐treatment (evaluable participants) compared with penicillin (very low certainty).
Cephalosporins may leads to lower incidence of relapse (evaluable participants) compared with penicillin (low certainty).
It is very uncertain whether cephalosporins changes adverse events (ITT analysis) compared with penicillin (very low certainty).
Macrolides showed no clear difference in resolution of symptoms post‐treatment (ITT analysis) compared with penicillin (low certainty).
Macrolides showed no clear difference in resolution of symptoms post‐treatment (evaluable participants) compared with penicillin (low certainty).
Macrolides showed no clear difference in incidence of relapse (evaluable participants) compared with penicillin (low certainty).
Macrolides showed no clear difference in adverse events (ITT analysis) compared with penicillin (low certainty).
It is very uncertain whether azithromycin changes clinical cure (ITT analysis) compared with amoxicillin (very low certainty).
Vitamin D showed no clear difference in mortality rate ( compared with placebo (low certainty).
Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in pulmonary exacerbations: number of pulmonary exacerbations compared with tobramycin (moderate certainty).
Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in survival: number of deaths compared with tobramycin (low certainty).
Summary of findings: colistimethate dry powder for inhalation… may leads to higher adverse events: number of treatment related adverse events compared with tobramycin (low certainty).